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A new assay was developed for the detection of 
hepatitis B virus (HBV) in human serum using 
amplification of a short viral DNA sequence by 
means of the polymerase chain reaction. As little 
as 0.4 fg viral DNA, corresponding to about 130 
genome equivalents, per ml serum could be de- 
tected after the amplification procedure. This as- 
say detected viral DNA in a number of patients 
with proven or suspected chronic HBV infection 
who were all negative for HBV DNA in the con- 
ventional hybridisation assay. We found HBV 
DNA in all of six HBeAg-positive and in three of 
eight HBeAg-negative HBsAg carriers, as well as 
in al l  of 11 patients with chronic liver disease 
with antibodies against the HBV core antigen 
(anti-HBc) as the sole marker for HBV infection, 
and in three of five apparently healthy individu- 
als showing only anti HBc. Thus, this method is 
an important improvement for the diagnosis of 
persistent HBV infections, especially in patients 
where a definitive serological diagnosis is not 
possible. 
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INTRODUCTION 
Information about the presence or absence of hepa- 
titis B virus (HBV) in the serum of an infected individ- 
ual is desirable in several instances: for the assessment 
of disease activity in persistent infection, for monitor- 
ing therapeutic trials of antiviral agents, or for the 
evaluation of the infectivity of an individual’s blood. 
The hepatitis B surface antigen (HBsAg) is the pri- 
mary marker for the diagnosis of acute or chronic hep- 
atitis B infection; however, although its presence is 
bound to the presence of viral genomic material in the 
liver, it correlates only roughly with viral replication 
and with the presence of infectious particIes in the cir- 
culation. The hepatitis B e antigen (HBeAg) is a clearly 
better but also indirect marker for the presence of virus 
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in the blood. By far the best diagnostic parameter in 
this respect is the viral DNA, which can be detected by 
a sensitive direct hybridisation assay [Bonino et al., 
1981; Berninger et al., 19821. The introduction of this 
test was one of the major improvements for the diag- 
nosis of hepatitis B. It has not only led to a better 
understanding of the pathogenesis of the disease, espe- 
cially of chronic HBV infection, but it is to date the 
most sensitive assay for the detection and assessment 
of the infectivity of an  HBV-infected individual [ Zyzik 
et al., 19861. However, even this method has a detec- 
tion limit of 105-106 virus particles per ml, which 
makes the exclusion of infectivity impossible; indeed, 
the infectivity of blood units determined negative for 
HBV DNA by the hybridisation assay could clearly be 
demonstrated [Krogsgaard et al., 19861. Recently, a 
highly sensitive and specific method for the detection of 
DNA using enzymatic amplification of DNA sequences 
was introduced, which allows the detection of even a 
single copy of a gene ISaiki et al., 1985; Mullis and 
Faloona, 19871. This test, known as polymerase chain 
reaction (PCR), was used initially to diagnose genetic 
abnormalities [Saiki et al., 1985; Verlaan-de Vries et 
al., 1986; Kogan et al., 19871, but has now also been 
adapted for the detection of viral pathogens, such a s  
papilloma virus [Shibata et al., 19881, human immu- 
nodeficiency virus [Kwok et al., 1987; Loche and Mach, 
1988; Laure et  al., 19881, and hepatitis B virus [ Larzul 
et al., 19881. The use of the thermostable polymerase of 
the bacterium Thermus aquaticus (Tag) [Saiki et al., 
19881 instead of the Klenow polymerase originally 
used [Saiki et al., 19851 greatly simplified this method 
and allowed its application for routine diagnostic pro- 
cedures with large numbers of samples. Using this 
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technique, we developed a sensitive and highly specific 
test for the detection of HBV DNA in serum. In this 
paper we describe our initial findings with this new 
assay. 
PATIENTS, MATERIALS, AND METHODS 
Blood samples were obtained from chronic HBsAg 
carriers, patients with chronic liver disease of un- 
known etiology, healthy individuals previously in- 
fected with hepatitis B with antibodies against HBsAg 
(anti-HBs) and against the core antigen of HBV (anti- 
HBc), healthy persons with anti-HBc only, and healthy 
controls without any HBV marker. 
HBV DNA was isolated from 250 pl serum by the 
method of Berninger et al. 119821 and dissolved in 20 p1 
0.01 M Tris, 0.001 M EDTA, pH 7.4 (TE buffer). 
Oligonucleotide primers were selected from con- 
served regions of the core gene of HBV according to the 
nucleotide sequence published by Ono et al. 119833: 
primer I (5’): CTGTGGAG’ITACTCTCGTGC (po- 
sition 1937-1960); primer I1 (3’ l: CTAACATTGAGAT- 
TCCCGAGATTGAGA (position 2434-2460). They 
were synthesized with a Biosearch 8700 DNA synthe- 
sizer (Biosearch, San Raffael, CA). 
Ampiification of HBV DNA was carried out by the 
polymerase chain reaction using a commercially avail- 
able reagent kit (Gene Amp@ DNA amplification kit, 
Perkin Elmer, Uberlingen, FRG) according to the man- 
ufacturers’ instructions. Two microliters of purified 
DNA were used for each assay; concentration of the 
oligonucleotide primers was 0.5 pM. Prior to the addi- 
tion of the Taq polymerase, samples were heated to 
100°C for 10 min. Thereafter the mixture was cooled 
down to 37°C and 2.5 U of Taq polymerase in 0.5 pl 
were added. Incubation conditions were 37°C for 2 min 
(annealing), 70°C for 3 min (DNA synthesis), and 92°C 
for 1 min (denaturation). After ten such cycles the an- 
nealing temperature was increased to 50°C for another 
30 cycles. After the amplification procedure 10 pl of 
sample were mixed with 1 pl gel loading buffer con- 
taining 50% sucrose, 0.05 M EDTA, 0.5 mg/ml xylene 
cyanol and 0.5 mg/ml bromophenol blue. Agarose gel 
electrophoresis on a 2% gel according to standard pro- 
cedures IManiatis e t  al., 19821 was then carried out. 
DNA was visualized by staining with ethidium bro- 
mide and transferred to a nylon membrane (Biodynem 
0.2 pore size, Pall BioSupport division, NY) according 
to Southern 119751. HBV-specific sequences were de- 
tected by hybridisation with an a-”P-labelled DNA 
probe specific for the region between the two primers. 
For the generation of this probe we used a 422 base 
pairs long fragment (nucleotide 1986-2408) [Ono et al., 
19831, which was obtained by digestion of HBV DNA 
by the restriction enzyme Bgl I1 and was subcloned into 
a pUC8 vector using standard methods [Maniatis et al., 
19821. The fragment was purified by agarose gel elec- 
trophoresis and used as  template for the synthesis of 
labelled DNA by the method of “oligolabelling” [Fein- 
berg and Vogelstein, 19831 with a “random primed 
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DNA labelling kit” (Boehringer Mannheim, FRG) ac- 
cording to the manufacturer’s instructions. 
For the direct detection of HBV DNA in serum with- 
out prior amplification the hybridisation assay de- 
scribed by Scotto et al. [ 19831 was used as  modified by 
Zyzik et al. 119861. HBV DNA was visualized using a 
RNA probe generated from total HBV DNA cloned into 
the plasmid pSP65. The radiolabelled probe was  pre- 
pared with the SPG-Riboprobe@ system as described by 
the manufacturer (Promega Biotec, Madison, WI). The 
detection limit of this test is about 0.3 pg of HBV DNA. 
Tests for HBsAg, anti-HBs, anti-HBc, HBeAg, and 
antibodies against HBeAg (anti-HBe) were performed 
by radioimmunoassay using commercially available 
kits (Abbott Laboratories, North Chicago, IL). 
RESULTS 
The sensitivity ofthe new HBV DNA assay was eval- 
uated by testing serial dilutions of a plasmid contain- 
ing the entire HBV DNA (Fig. 1 ). After 30-40 cycles of 
the PCR, 0.01 fg of HBV DNA was  clearly detected by 
Southern blot analysis. As little a s  1 fg DNA was vis- 
ible after amplification in the ethidium-bromide- 
stained agarose gel. Accordingly, the minimum detect- 
able HBV DNA concentration in serum should be 
about 0.4 fg/ml, taking the concentration step during 
the DNA preparation and the amount of material used 
for the PCR (2 PI) into consideration. 
The clinical significance of the new assay could be 
demonstrated by the evaluation of a panel of sera 
which all had been found negative with the conven- 
tional DNA test (Table I). Six individuals who were 
HBsAg and HBeAg positive were found to be DNA pos- 
itive after the amplification procedure, whereas of 
eight HBeAg-negative HBsAg carriers only three 
showed HBV DNA after the PCR. All of the carriers 
were asymptomatic. Analysis of sera of 11 patients 
with chronic liver disease who showed anti-HBc as  the 
only marker of HBV infection revealed that  all were 
DNA-positive (Fig. 2); on the other hand DNA was de- 
tectable only in three of five healthy individuals with 
anti-HBc only. Ten healthy persons infected previously 
with hepatitis B and ten individuals without any sero- 
logical indication of an HBV infection served as con- 
trols; all were negative for HBV DNA. All these results 
were obtained by the Southern blot procedure; how- 
ever, most of the positive sera were detectable already 
on the agarose gel electrophoresis. 
DISCUSSION 
We established a new assay for the detection of HBV 
in serum using the PCR for amplification of an  HBV 
DNA sequence 524 base pairs long, which was then 
identified by agarose gel electrophoresis and Southern 
blotting. This test detects about 0.4 fg HBV DNA, or 
about 130 viral particles, per ml serum, showing a 
nearly 1,000-fold higher sensitivity than the direct hy- 
bridisation assay, which has a detection limit of about 
0.3 pg HBV DNA, corresponding to lo5 genome equiv- 
306 Sumazaki et al. 
524 bp- 
4 3  4 3  
10 10 1810 1 Id18 0 10 10 1810 1 1d180 
fg HBV DNA 
Fig 1. Detection of HBV DNA in serial dilutions of a plasmid containing the entire HBV DNA; the 
amount of DNA which was amplified is indicated. The electrophoretic (left) and the Southern blot (right) 
analysis of the amplified 524 base pairs long DNA sequence is shown. 
TABLE I. Evaluation of Sera of Controls and Individuals 
With Different Forms of HBV Infection for HBV DNA by the 
PCR Amplification Procedure* 
No. subjects 
DNA after PCR 
Serological status Total Positive Negative 
HBsAg ' , 
HBeAg + , anti-HBe- 6 6 0 
HBsAg + , 
HBeAg-, anti-HBe- 1 0 1 
HBsAg + , 
HBeAg-, anti-HBe ' 7 3 4 
Only anti-HBc + , 
chronic liver disease 11 11 0 
Only anti-HBc ' , 
healthy 5 3 2 
Anti-HBs ' , anti-HBc + 10 0 10 
No HBV marker 10 0 10 
*All sera were negative for DNA with the conventional hybrldisation 
assay. 
alents per ml [Zyzik e t  al., 19861. Thus, the sensitivity 
of our test is comparable to tha t  of a similar assay 
described recently by L a r d  et al. 119881. The specific- 
ity of the test is guaranteed 1) by the use of Southern 
blotting showing the correct molecular weight of the 
amplified sequence, and 2) by using as probe a DNA 
sequence between the two primers which excludes the 
possibility of a false positive reaction due to hybrid- 
isation with primer sequences. 
Sera of 40 individuals with markers of a previous 
HBV infection and sera of ten healthy controls without 
any markers of hepatitis B were analysed for the pres- 
ence of HBV DNA by this assay. All sera were negative 
for HBV DNA in a conventional direct hybridisation 
test. After amplification the presence of HBV DNA 
could be demonstrated unequivocally in the majority of 
apparently healthy HBsAg carriers including all 
HBeAg-positive individuals, and in 11 patients with 
chronic liver disease with anti-HBc as the only marker 
of hepatitis B infection; in addition HBV DNA was 
found in three of five healthy individuals who were 
only anti-HBc positive. 
These results show the high sensitivity of the new 
assay and demonstrate its usefulness for the diagnosis 
of different forms of HBV infection. Furthermore, our 
findings confirm and expand results of investigations 
using the conventional hybridisation assay for the  de- 
tection of HBV DNA. These earlier studies showed tha t  
viral replication, as demonstrated by the  presence of 
viral DNA in the circulation, is correlated with the  
presence of HBeAg and with symptomatic liver disease 
[Bonino et al., 1981; Berninger et al., 1982; Scotto et 
al., 1983; Zyzik et al., 19861. Our data fit well into this 
pattern. All HBeAg-positive individuals tested were 
indeed also DNA positive, although they were appar- 
ently asymptomatic. These cases were selected for the 
amplification procedure because they were negative in 
the conventional hybridisation assay, which is positive 
in the vast majority of HBeAg-positive carriers; thus, 
this result could well mean tha t  all HBeAg-positive 
HBsAg carriers are  viremic. Even more important 
seems our finding tha t  all patients with chronic liver 
disease showing anti-HBc as the only HBV marker 
were DNA positive, as well as three of five healthy 
individuals showing this serological profile. Using the 
direct hybridisation assay, Seelig et al. 119851 could 
detect HBV DNA in 9 of 50 patients with liver disease 
showing this pattern, whereas Brechot et al. [1985] 
were unable to demonstrate HBV DNA in the serum of 
11 similar patients, although 9 of them had HBV DNA 
in their livers. Healthy individuals with anti-HBc only 
were found to be HBV DNA negative in the direct hy- 
bridisation assay by most authors [Scotto et al., 1983; 
Zyzik et al., 19861, nevertheless it is known from sev- 
eral studies tha t  at least some of these individuals are  
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Fig. 2. Analysis of sera of 1 1  patients (1-1 1 )  with chronic liver disease and anti-HBc a s  the sole 
serological marker. 0 =- negative control. a: Electrophoretic ( lef t )  and Southern blot (right) analysis of 
the amplified sequence; exposure time was 2 h. b: Same Southern blot a s  in panel a but  exposed for 8 hr. 
showing clear positive signals for sera 8 and 11 
chronic carriers of HBV (the so-called low-level carri- 
ers) and are able to transmit the infection via blood 
transfusions [Hopkins et al., 1982; Sugg et  al., 19821. 
Such individuals can be well identified by the proce- 
dure described here. Thus, the detection of HBV DNA 
after amplification by PCR may become an  indispens- 
able method to clarify the extent of HBV infection in 
cases were a definitive serological diagnosis is not pos- 
sible, e.g., where anti-HBc is the sole serological 
marker for hepatitis B infection. 
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